UPDATE: BTIG Starts BioAtla Inc. (BCAB) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/4/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
UPDATE: Credit Suisse Starts BioAtla Inc. (BCAB) at Outperform
January 11, 2021 5:01 AM EST(Updated - January 11, 2021 6:23 AM EST)
Credit Suisse analyst Tiago Fauth initiates coverage on BioAtla Inc. (NASDAQ: BCAB) with a Outperform rating and a price target of $49.00.
The analyst comments "The companys two lead proprietary programs targeting AXL (BA3011) and ROR2 (BA3021) are antibody-drug conjugates (ADC) designed with BCABs proprietary conditionally active biologics (CAB) technology. CAB molecules have... More
UPDATE: Jefferies Starts BioAtla Inc. (BCAB) at Buy Ahead of Two Separate Phase 2 Readouts
January 11, 2021 4:43 AM EST(Updated - January 11, 2021 8:52 AM EST)
Jefferies analyst Biren Amin initiates coverage on BioAtla Inc. (NASDAQ: BCAB) with a Buy rating and a price target of $51.00 ahead of Ph2 interim readouts in H2' 21. Jefferies was joint book-running manager in BCAB's... More
JPMorgan Starts BioAtla Inc. (BCAB) at Overweight
January 11, 2021 4:42 AM ESTJPMorgan initiates coverage on BioAtla Inc. (NASDAQ: BCAB) with a Overweight rating and a price target of $45.00.
For an analyst ratings summary and ratings history on BioAtla Inc. click here. For more ratings news on BioAtla Inc. click here.
Shares of BioAtla Inc. closed at $38.25 yesterday.
... More